Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide,
enzalutamide and darolutamide in Phase III clinical trials involving patients with …

Introduction: Studies using apalutamide, enzalutamide, or darolutamide have shown
improved metastasis free survival (MFS) rates, leaving clinicians with a dilemma of choosing …

Management of non-metastatic castration-resistant prostate cancer (nmCRPC) has
undergone a paradigm shift with next-generation androgen receptor inhibitors. However …

Purpose: No published head-to-head randomized trials have compared the safety and
efficacy of darolutamide vs apalutamide or enzalutamide in nonmetastatic castration …

Purpose: To indirectly compare the efficacy and safety of systemic therapies used for
patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Methods: The …

Introduction Apalutamide and darolutamide are next-generation androgen receptor
inhibitors that have demonstrated superior efficacy compared to placebo in men with non …

Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have historically
had few treatment options. Recently, randomized controlled trials have examined the benefit …

Non-metastatic castration-resistant prostate cancer (nmCRPC) is a heterogeneous disease
with variable potential in developing into overt metastases. It is an area of increased unmet …

Background The most recent overall survival (OS) and adverse event (AE) data have not
been compared for the three guideline-recommended high-risk non-metastatic castration …

The PROSPER, SPARTAN, and ARAMIS trials demonstrated the efficacy of enzalutamide,
apalutamide, and darolutamide, respectively, to extend metastasis-free survival in men with …